CTC Bio

CTC Bio EBIT per Share

The EBIT per Share of CTC Bio (060590.KQ) as of Oct 29, 2026 is 328.26 KRW. In the previous year, EBIT per Share was -211.46 KRW — a change of -255.23% (higher).

EBIT per Share

328.26KRW

YoY

-255.23%

Last updated:

EBIT per Share of CTC Bio is 2025 328.26 KRW. EBIT per Share of CTC Bio was 2024 -211.46 KRW. It decreases by -255.23% higher compared to the previous year.

The CTC Bio EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
-396.93 KRW
Jan 1, 2019
-284.53 KRW
Jan 1, 2020
-370.28 KRW
Jan 1, 2021
-187.01 KRW
Jan 1, 2022
172.60 KRW
Jan 1, 2023
-692.87 KRW
Jan 1, 2024
-211.46 KRW
Jan 1, 2025
328.26 KRW
The CTC Bio EBIT per Share history
YEAREBIT per ShareYoY
328.26KRW-255.23%
-211.46KRW-69.48%
-692.87KRW-501.43%
172.60KRW-192.29%
-187.01KRW-49.49%
-370.28KRW+30.14%
-284.53KRW-28.32%
-396.93KRW-51.84%
-824.12KRW+495.29%
-138.44KRW-200.02%
138.41KRW+2,284.58%
5.80KRW-94.75%
110.49KRW-81.17%
586.67KRW+1,340.14%
40.74KRW-87.05%
314.46KRW+6.15%
296.23KRW+25.69%
235.69KRW+57.29%
149.85KRW+61.93%
92.54KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CTC Bio Stock analysis

What does CTC Bio do? CTC Bio, Inc. generates revenue through the manufacture and sale of pharmaceuticals, including anticancer agents, antibiotics, bone injury treatments, antiulcer agents, and blood flow stimulants. The company also produces veterinary drugs such as vaccines, antibiotics, immune enhancers, enzymes, organic acid, and avian influenza-related agents, alongside animal feed supplements like pigments, kapok seed meal, and sesame meal. Functional food products, including enzymes and lactobacillus for dairy applications, form another revenue stream. The firm distributes these products domestically and internationally, targeting healthcare providers, veterinarians, and food manufacturers. The company's pharmaceutical segment serves medical professionals seeking treatments for cancer, infections, and gastrointestinal issues. Veterinary drug sales cater to animal health practitioners requiring vaccines and antibiotics for livestock. Animal feed supplements are sold to agricultural businesses, while functional food ingredients target dairy producers. CTC Bio, Inc. leverages its in-house pharmaceutical manufacturing technology and know-how to support product development and maintain competitive pricing. Revenue streams include direct sales of pharmaceuticals, veterinary drugs, animal feed supplements, and functional food ingredients. Domestic markets absorb the majority of these products, with international distribution expanding its reach. The company's focus on integrated production of pharmaceuticals, animal health solutions, and functional food components ensures consistent demand across multiple industry segments. CTC Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CTC Bio stock

EBIT per Share of CTC Bio is 328.26 KRW in 2025.

EBIT per Share of CTC Bio changed from -211.46 KRW to 328.26 KRW, representing a -255.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share CTC Bio since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — CTC Bio

All Key Metrics — CTC Bio